Prostate cancer risk assessment model: A scoring model based on the Swedish Family-Cancer Database

Journal of Medical Genetics

Volumn 49, Issue 5, 2012, Pages 345-352

  Roudgari, Hassan ^a,b   Hemminki, Kari ^c,d   Brandt, Andreas ^c   Sundquist, Jan ^d,e   Fallah, Mahdi ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DATA BASE; ESOPHAGUS CARCINOMA; FAMILY HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SWEDEN;

EID: 84864106531     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2011-100290     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225e49.
2. Drake R. Prostate cancer: the mire of modifiable risk factors. Nat Rev Urol 2010;7:362.
3. Isbarn H, Karakiewicz PI. Risk factors: improved risk stratification for prostate cancer. Nat Rev Urol 2009;6:355e6.
4. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 1999;35:272e7.
5. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997;70:679e81.
6. Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004;5:151e75.
7. Galosi AB, Montironi R, Mazzuchelli R, Muzzonigro G. Clinical pathology of prostate cancer: focus on diagnosis, predictive and prognostic factors and quality indicators. Arch Ital Urol Androl 2007;79:45e51.
8. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993;150:106e9.
9. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948e54.
10. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008;28:323e31.
11. Stenman UH, Leinonen J, Zhang WM, Finne P, Wu P. The clinical importance of free prostate-specific antigen (PSA). Curr Opin Urol 1998;8:393e9.
12. Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010;102:1336e43.
13. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng ZD, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006;98:529e34.
14. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107:882e91.
15. Lawrentschuk N, Daljeet N, Trottier G, Crawley P, Fleshner NE. An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer. BJU Int 2011;108:E190e5.
16. Bowen DJ, Hannon PA, Harris JR, Martin DP. Prostate cancer screening and informed decision-making: provider and patient perspectives. Prostate Cancer Prostatic Dis 2011;14:155e61.
17. Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schroder FH, Tubaro A. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int 2011;107:716e21.
18. MacInnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA, McGuffog L, Kote-Jarai Z, Guy M, O'Brien LT, Hall AL, Wilkinson RA, Sawyer E, Ardern-Jones AT, Dearnaley DP, Horwich A, Khoo VS, Parker CC, Huddart RA, Van As N, McCredie MR, English DR, Giles GG, Hopper JL, Easton DF. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 2011;35:549e56.
19. Hemminki K, Ji JG, Brandt A, Mousavi SM, Sundquist J. The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 2010;126:2259e67.
20. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. Oncologist 2009;14:1209e17.
21. Hemminki K, Granstrom C. Risk for familial breast cancer increases with age. Nat Genet 2002;32:233.
22. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789e94.
23. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schroder FH. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol 2006;175:1332e6.
24. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton DF, Pharoah PD. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45:425e31.
25. Hemminki K, Chen BW. Familial association of prostate cancer with other cancers in the Swedish family-cancer database. Prostate 2005;65:188e94.
26. Gronberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997;146:552e7.
27. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425e38.
28. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin R, Berthon R, Cussenot O, Demenais F. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003;67:125e37.
29. Verhage BAJ, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE, Beaty TH, Catalona WJ, Kiemeney LA. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 2001;57:97e101.
30. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, Koivisto PA, Tammela TL, Deshmukh S, Ou L, Bailey-Wilson JE, Schleutker J. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007;121:257e67.
31. Xu JF, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Gronberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genetics 1998;20:175e9.
32. Dong JT, Boyd JC, Frierson HF. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 2001;49:166e71.
33. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358e66.
34. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898e905.
35. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474e80.
36. Roudgari H, Miedzybrodzka ZH, Haites NE. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models. Fam Cancer 2008;7:199e212.
37. Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, Brassell SA. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology 2011;78:110e15.
38. Lee SH, Park KK, Chung MS, Chung BH. Clinical features of familial or hereditary prostate cancer in korean men: a pilot study. Korean J Urol 2011;52:9e12.
39. Dong JT, Li CL, Sipe TW, Frierson HF. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001;7:304e8.
40. Hemminki K, Mutanen P. Parental cancer as a risk factor for nine common childhood malignancies. Br J Cancer 2001;84:990e3.
41. Boergermann C, Vom DF, Becker M, Swoboda A, Ketteniss O, Rubben H. PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! Cancer Epidemiol Biomarkers Prev 2011;20:1190e5.
42. Mina K, Fritschi L, Johnson KC; The Canadian Cancer Registries Epidemiology Research Group. An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. Nutr Cancer 2008;60:222e6.
43. Park K, Kim JH, Jeon HG, Byun SS, Lee E. Influence of IGFBP3 Gene Polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk korean men. Urology 2010;75:1516.e1e7. 1-6-2010. Ref Type: Abstract.
44. Carroll JC, Cappelli M, Miller F, Wilson BJ, Grunfeld E, Peeters C, Hunter AG, Gilpin C, Prakash P. Genetic services for hereditary breast/ovarian and colorectal cancersdphysicians' awareness, use and satisfaction. Community Genet 2008;11:43e51.
45. Frank TS. Hereditary risk of breast and ovarian carcinoma: the role of the oncologist. Oncologist 1998;3:403e12.
46. Srivastava A, McKinnon W, Wood ME. Msk of breast and ovarian cancer in women with strong family histories. Oncology (Williston Park) 2001;15:889e902.
47. Stattin P. Commentary: fatherhood status and prostate cancer risk-the jury is still out. Int J Epidemiol 2011;40:488.
48. Qu Y, Wang Y. Nonparametric inference on the E/O ratio in model validation. Stat Med 2008;27:3340e9.
49. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115e21.
50. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev 2008;17:1843e8.
51. Hosain GM, Sanderson M, Du XL, Chan W, Strom SS. Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. Cent Eur J Public Health 2011;19:30e4.